U.S. Health Care REITs Stock News

NYSE:MANE
NYSE:MANEPharmaceuticals

Assessing Veradermics (MANE) Valuation After A Sharp 72% One Month Share Price Move

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...
NasdaqGS:POOL
NasdaqGS:POOLRetail Distributors

Pool CEO Shakeup And Delayed Investor Day Test Undervalued Thesis

Pool Corporation (NasdaqGS:POOL) has announced the immediate departure of CEO Peter D. Arvan. John B. Watwood has been appointed as the new President and CEO, with John E. Stokely becoming Executive Chair. The company has postponed its upcoming Investor Day following the leadership change. Pool enters this leadership transition after a period of weak share price performance, with NasdaqGS:POOL at $188.09 and showing a 10.3% decline over the past week and 35.2% decline over the past year...
NYSE:LEU
NYSE:LEUOil and Gas

Centrus Energy Q1 Margin Compression Challenges Bullish HALEU Profitability Narrative

Centrus Energy (LEU) opened Q1 2026 with revenue of US$76.7 million and basic EPS of US$0.51, against a backdrop of forecast earnings growth of about 7.0% a year and revenue growth around 5.1%. Over recent quarters the company has seen revenue range between US$73.1 million and US$154.5 million with basic EPS between US$0.21 and US$3.21. Trailing 12 month EPS sits at US$3.25 on revenue of US$452.3 million and net income of US$60.6 million, framing a set of results where profit growth and...
NasdaqGM:OMER
NasdaqGM:OMERPharmaceuticals

Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects

What recent performance signals for Omeros (OMER) Without a single defining headline driving trading, Omeros (OMER) has still drawn attention after a strong month and past 3 months, alongside sizeable 1 year and 3 year total returns. At a recent price of $14.83 and a market cap of about $1.06b, the stock reflects a clinical stage pipeline built around immunologic and rare disease programs rather than current product revenue. See our latest analysis for Omeros. For context, Omeros has paired a...
NYSE:MP
NYSE:MPMetals and Mining

Is It Too Late To Consider MP Materials (MP) After Rare Earth Supply Chain Tailwinds?

To figure out whether MP Materials stock still offers value after its strong run, you need to separate a compelling story about rare earths from what the current share price already reflects. The stock last closed at US$72.65, with returns of 18.5% over 7 days, 42.0% over 30 days, 32.2% year to date, 207.6% over 1 year, 221.7% over 3 years and 192.9% over 5 years, so recent performance is front of mind for many investors. Recent news around rare earth supply chains and US focused production...
NasdaqGS:ASO
NasdaqGS:ASOSpecialty Retail

Is It Too Late To Consider Academy Sports and Outdoors (ASO) After Strong Five Year Return?

Wondering whether Academy Sports and Outdoors at around US$54.46 is still priced attractively, or if most of the easy upside is gone? This article focuses squarely on what the numbers say about value. The stock has returned 4.4% year to date and 36.7% over the past year, while the past 30 days and 7 days show declines of 4.8% and 0.7%. This can change how the market is thinking about risk and opportunity. Recent coverage around Academy Sports and Outdoors has centered on how the business is...
NYSE:ITT
NYSE:ITTMachinery

ITT (ITT) Q1 Margin Compression Tests Bullish Growth Narrative

ITT (ITT) opened 2026 with Q1 revenue of US$1.2 billion and basic EPS of US$0.89, setting the tone for how the year could unfold against its recent track record. The company has seen quarterly revenue move from US$913 million in Q1 2025 to US$1.2 billion in Q1 2026, while basic EPS ranged from US$1.33 in Q1 2025 to US$1.65 in Q4 2025 before the latest Q1 print. This puts the focus firmly on how much of this top line is flowing through to margins. See our full analysis for ITT. With the latest...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

Has The Recent Pullback In Zoetis (ZTS) Opened A New Valuation Opportunity?

If you are wondering whether Zoetis at around US$111 is a bargain or a value trap, this article will explain what the current price might be implying about the stock. The stock has recently retreated, with returns of 2.3% over 7 days, 6.0% over 30 days, 11.7% year to date, and 27.6% over 1 year. This may have shifted how the market views its risk and reward trade off. Recent coverage has focused on Zoetis as a major animal health company, highlighting how the sector can be influenced by...
NYSE:CPNG
NYSE:CPNGMultiline Retail

Coupang (CPNG) Q1 EPS Loss Revives Debate On Path To Sustainable Profitability

Coupang (CPNG) opened Q1 2026 with revenue of about US$8.5b and a basic EPS loss of US$0.15, alongside a trailing twelve month basic EPS loss of US$0.09 on revenue of roughly US$35.1b. This keeps the focus firmly on how efficiently that scale is translating into earnings. Over recent quarters the company has seen revenue move from about US$7.9b in Q1 2025 to US$9.3b in Q3 2025 before landing at US$8.5b this quarter. Over the same period, quarterly basic EPS has swung from a profit of US$0.06...
NasdaqCM:PHOE
NasdaqCM:PHOEConstruction

Assessing Phoenix Asia Holdings (NasdaqCM:PHOE) Valuation After Sharp Short Term Share Price Swings

Phoenix Asia Holdings (PHOE) has drawn fresh attention after recent trading, with the stock last closing at $28.60. Investors are weighing its substructure construction focus in Hong Kong against recent short term share price moves. See our latest analysis for Phoenix Asia Holdings. The recent 1 day share price return of 39.14% decline contrasts sharply with the 7 day share price return of 83.92% and the year to date share price return of 76.11%. The 1 year total shareholder return is very...
NYSE:NABL
NYSE:NABLSoftware

Assessing N-able (NABL) Valuation After Narrower Q1 2026 Net Loss Draws Fresh Investor Attention

Q1 earnings highlight a narrower loss N-able (NABL) reported first quarter 2026 earnings with a net loss of US$615,000, compared with a net loss of US$7.16 million a year earlier, drawing fresh attention to the stock. See our latest analysis for N-able. The earnings update comes after a mixed share price stretch, with a 10.17% 1 month share price return, a 27.26% year to date share price decline, and a 25.63% 1 year total shareholder return loss, suggesting momentum has been weak despite...
NasdaqGS:OUST
NasdaqGS:OUSTElectronic

Ouster (OUST) Q1 Loss Resurfacing After Q4 Profit Tests Bullish Profitability Narrative

Ouster (OUST) opened 2026 with Q1 revenue of US$48.6 million and a basic EPS loss of US$0.28, alongside a net loss of US$17.5 million. On a trailing 12 month basis, revenue sits at US$185.3 million and basic EPS is a loss of US$0.95 against a net loss of US$55.8 million. Over the past reported quarters, revenue has moved from US$30.1 million in Q4 2024 to US$32.6 million in Q1 2025 and then to US$48.6 million in Q1 2026, with quarterly EPS losses ranging between US$0.48 and US$0.28 across...
NYSE:INGM
NYSE:INGMElectronic

Ingram Micro Balances Share Sale With Buyback And Cybersecurity Expansion

Ingram Micro Holding (NYSE:INGM) is seeing a substantial secondary offering by its principal shareholder, an affiliate of Platinum Equity, shifting a meaningful block of ownership. The company has authorized a $30 million share repurchase from the underwriters in connection with this offering, signaling active capital management around the transaction. Separately, Ingram Micro has been selected as a global distribution partner for Huntress, a cybersecurity platform, expanding its reach in...
NYSE:CBT
NYSE:CBTChemicals

Is It Time To Reassess Cabot (CBT) After Its Recent Share Price Strength?

If you are wondering whether Cabot is trading at an attractive price today, or if the recent enthusiasm already reflects its value, this breakdown will help you put the current share price in context. Cabot's stock recently closed at US$82.41, with returns of 8.8% over the past week, 10.8% over the past month, 22.9% year to date and 15.7% over the past year, which can influence how you think about upside and risk. Recent coverage around Cabot has focused on giving investors evergreen context...
NasdaqGS:ALKT
NasdaqGS:ALKTSoftware

Is Alkami Technology (ALKT) Starting To Look Attractive After A 40% One-Year Share Price Fall

If you are wondering whether Alkami Technology at around US$16.75 is starting to look like value or still carries more risk than reward, the recent price history gives you a useful starting point. The stock has moved 2.0% over the last 7 days, is roughly flat over 30 days with a 0.2% decline, but is down 26.1% year to date and 40.2% over the past year, set against a 28.8% gain over 3 years and a 48.7% decline over 5 years. These mixed returns have kept attention on how the business is being...
NasdaqGS:PATK
NasdaqGS:PATKAuto Components

Is It Too Late To Consider Patrick Industries (PATK) After Recent 30 Day Share Price Slide?

Wondering if Patrick Industries, at a last close of US$95.90, offers good value or if the easy money has already been made? These valuation checks aim to give you a clearer picture before you decide your next move. The stock has had a mixed run, with a 2.8% return over the last 7 days, a 15.8% decline over 30 days, a 20.0% return over 1 year, and 132.9% over 3 years. Recent news coverage has focused on Patrick Industries as part of broader discussions around the Auto Components sector and...
NasdaqGS:ADP
NasdaqGS:ADPProfessional Services

Is It Time To Reassess ADP (ADP) After Its 30% One-Year Share Price Slide

If you are wondering whether Automatic Data Processing (ADP) looks attractively priced after a rough patch, this article will help you assess what you might really be paying for with the stock. At a last close of US$207.20, ADP's share price reflects a 3.7% decline over the past week, a 1.4% gain over the past month, and returns of an 18.1% decline year to date and a 30.4% decline over the past year. Those moves have kept ADP on many investors' watchlists, with recent headlines keeping...
NasdaqGS:APEI
NasdaqGS:APEIConsumer Services

American Public Education Uses APUS Milestone To Highlight Growth Story

American Public University System, part of American Public Education (NasdaqGS:APEI), is preparing its 30th annual commencement. The ceremony includes a record graduating class for APUS. APUS is adding a dedicated doctoral hooding event and expanded graduate celebrations. Additional ceremonies and student recognition initiatives are planned around the commencement. American Public Education, through APUS, focuses on online higher education for adult learners, including military and public...
NasdaqGS:SEDG
NasdaqGS:SEDGSemiconductor

SolarEdge Technologies (SEDG) Q1 Loss Narrows Yet Leaves Margin Recovery Narrative Unproven

Q1 2026 results in focus SolarEdge Technologies (SEDG) opened 2026 with Q1 revenue of US$310.5 million and a basic EPS loss of US$0.94, alongside trailing twelve month revenue of US$1.28 billion and a basic EPS loss of US$5.99. Over recent quarters the company has seen revenue move from US$196.2 million in Q4 2024 to between roughly US$219.5 million and US$340.2 million through 2025. Over the same period, quarterly basic EPS has ranged from a loss of US$0.84 to a loss of US$5.00, setting up...
NasdaqGS:FTRE
NasdaqGS:FTRELife Sciences

Is It Too Late To Consider Fortrea Holdings (FTRE) After Its Recent Share Price Surge?

If you are wondering whether Fortrea Holdings at US$15.64 is still offering value after a strong run, or if you are late to the story, this article focuses on what the current price might be implying. The stock has moved sharply, with returns of 48.1% over the last 7 days, 73.6% over the last 30 days and 177.8% over the last year, although year to date it sits at a 7.0% decline. Recent market attention has centered on Fortrea's position within the life sciences and pharmaceutical services...